Phenotype Characterization of Heart Failure with Preserved Ejection Fraction in Medical Device and Surgical Trials
Overall, 16 out of 24 trials have at least demonstrated safety and feasibility. However, despite many trials of a medical device or surgical procedure showing proof of concept to treat HFpEF phenotypes, they do not provide sufficient evidence of long-term benefit. More robust and phenotype-based clinical trials are needed to ensure evidence-based solutions are developed in HFpEF.
Authors
- Aamir Hameed (ORCID: https://orcid.org/0000-0002-9242-6185)
- Francesco Fioretti (ORCID: https://orcid.org/0000-0001-7174-8604)
- Kenan Araz (ORCID: https://orcid.org/0000-0003-2802-5579)
- Javed Butler (ORCID: https://orcid.org/0000-0003-4267-6933)
- Mohammed Obaidan
- Shameem Ladak (ORCID: https://orcid.org/0000-0003-0476-4983)
Institutions
- University College Dublin (IE)
- Trinity College (CA)
- Trinity College Dublin (IE)
- University of Medicine and Health Sciences (KN)
- University of Mississippi (US)
- Baylor Medical Center at Garland (US)
- Regenerative Medicine Institute (MX)
- Dublin City University (IE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1002/ehf2.15401
- Citations
- 1
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39